Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Maxcyte (MXCT) Return on Equity (2021 - 2025)

Historic Return on Equity for Maxcyte (MXCT) over the last 5 years, with Q3 2025 value amounting to 0.25%.

  • Maxcyte's Return on Equity fell 800.0% to 0.25% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25%, marking a year-over-year decrease of 800.0%. This contributed to the annual value of 0.19% for FY2024, which is 300.0% down from last year.
  • Maxcyte's Return on Equity amounted to 0.25% in Q3 2025, which was down 800.0% from 0.23% recorded in Q2 2025.
  • Maxcyte's Return on Equity's 5-year high stood at 0.06% during Q1 2022, with a 5-year trough of 0.25% in Q3 2025.
  • In the last 5 years, Maxcyte's Return on Equity had a median value of 0.16% in 2023 and averaged 0.14%.
  • As far as peak fluctuations go, Maxcyte's Return on Equity surged by 100bps in 2022, and later tumbled by -800bps in 2025.
  • Maxcyte's Return on Equity (Quarter) stood at 0.07% in 2021, then dropped by -28bps to 0.09% in 2022, then plummeted by -76bps to 0.16% in 2023, then dropped by -20bps to 0.2% in 2024, then fell by -26bps to 0.25% in 2025.
  • Its Return on Equity was 0.25% in Q3 2025, compared to 0.23% in Q2 2025 and 0.21% in Q1 2025.